Santander and EIB provide €2 billion to support European companies affected by COVID-19 via credit lines for early payment of
![The Multipoint Group and Qualys announce long-term strategic collaborations and geographic expansions - The Madras Tribune The Multipoint Group and Qualys announce long-term strategic collaborations and geographic expansions - The Madras Tribune](https://img.einnews.com/facebook/323041/pioneer-and-leading-provider.jpeg)
The Multipoint Group and Qualys announce long-term strategic collaborations and geographic expansions - The Madras Tribune
![Introducing PIONEER: a project to harness big data in prostate cancer research | Nature Reviews Urology Introducing PIONEER: a project to harness big data in prostate cancer research | Nature Reviews Urology](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41585-020-0324-x/MediaObjects/41585_2020_324_Fig1_HTML.png)
Introducing PIONEER: a project to harness big data in prostate cancer research | Nature Reviews Urology
![PDF) Predicting the pulmonary effects of long-term e-cigarette use: are the clouds clearing? | European Respiratory Review PDF) Predicting the pulmonary effects of long-term e-cigarette use: are the clouds clearing? | European Respiratory Review](https://i1.rgstatic.net/publication/357778857_Predicting_the_pulmonary_effects_of_long-term_e-cigarette_use_are_the_clouds_clearing/links/61df1293034dda1b9ef198d7/largepreview.png)
PDF) Predicting the pulmonary effects of long-term e-cigarette use: are the clouds clearing? | European Respiratory Review
![Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial - The Lancet Diabetes & Endocrinology Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial - The Lancet Diabetes & Endocrinology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/409898c8-a4b5-4ff3-865f-ba8c1ef4d929/gr1.jpg)
Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial - The Lancet Diabetes & Endocrinology
![Pioneer factors as master regulators of the epigenome and cell fate | Nature Reviews Molecular Cell Biology Pioneer factors as master regulators of the epigenome and cell fate | Nature Reviews Molecular Cell Biology](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41580-022-00464-z/MediaObjects/41580_2022_464_Fig1_HTML.png)